We’re experiencing issues for some mobile devices with our ARTG dataset filter function. We apologise for any inconvenience while we work to fix this.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (291)
- COVID-19 (164)
- Safety monitoring and information (115)
- Compliance and enforcement (90)
- Legislation (78)
- Manufacturing (60)
- Vaping hub (57)
- Labelling and packaging (42)
- Import and export (37)
- Medicinal cannabis hub (28)
- Scheduling (national classification system) (27)
- Sunscreens (20)
- Weight loss products (18)
- Shortages and supply disruptions (11)
- Committees and advisory bodies (9)
- Cosmetics (6)
- Unique Device Identification (UDI) hub (5)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
1288 result(s) found, displaying 1276 to 1288
-
Media releasesOn 4 May 2011 the TGA is going to launch its new corporate website.
-
Media releasesAustralia's medicines regulator, the Therapeutic Goods Administration, has today issued precautionary advice to doctors not to give patients a second dose of the vaccine Pneumovax 23 pending completion of an investigation into an increased rate of adverse events in people receiving the vaccine for the second time.
-
Media releasesTGA is conducting a panel-led review to explore ways to improve transparency and public engagement in its regulatory work.
-
Regulatory decision noticesTherapeutic Goods Order No. 1 of 2010.
-
Media releasesThe Therapeutic Goods Administration (TGA) officially launched a new organisational structure on 1 July 2010.
-
Media releasesThe Therapeutic Goods Administration (TGA) has approved an extension to the shelf life for Tamiflu (oseltamivir) from five to seven years, when stored below 25°C. This extension is effective from 1 May 2009.
-
Regulatory decision noticesThis Order may be cited as the Therapeutic Goods (Articles that are not Medical Devices) Order No. 2 of 2004.
-
Regulatory decision noticesListing notice - tocotrienols complex - palm
-
Regulatory decision noticesListing notice - lactoferrin - bovine, colloidal anhydrous silica or silicon dioxide, glucosamine sulfate-potassium chloride complex or glucosamine sulfatesodium chloride complex, R,S- or R-alpha lipoic acid, levocarnitine, acctyllevocarnitine hydrochloride, propionyllcvocarnitine hydrochloride, levocarnitine hydrochloride, levocarnitine tartrate, levocarnitine fumarate or levocarnitine magnesium citrate, bromclain, lecithin, soy -soy phosphatidylserine-enriched
-
Regulatory decision noticesListing notice - colloidal anhydrous silica or silicon dioxide
-
Regulatory decision noticesListing notice - hydroxycitric acid, potassium hydroxycitrate, sodium hydroxycitrate, calcium hydroxycitrate, squalene, fresh leaf extract of alfalfa (Medicago sativa), Kunzea ambigua essential oil, dried green lipped mussel (Perna canaliculus)
-
Regulatory decision noticesListing notice - sodium selenite, selenomethionine, selenocysteine, high selenium yeast, Bifidobacterium longum strain BB536, beta-hydroxy-beta-methylbutyric acid, calcium beta-hvdroxy-beta-methylbutyrate, sodium beta-hydroxy-beta-methylbutyrate
-
Regulatory decision noticesListing notice - ubidecarenone, honey